Rick Hancock

Interim President & CEO

Rick Hancock has been a member of the Avid Bioservices Board of Directors since November 2017 and currently serves as the interim President and CEO. He has held a variety of executive positions in biotechnology for over thirty five years, most recently as President and CEO of Althea Technologies where he established its biologics and drug product contract manufacturing services and grew the business from inception to a recognized world leading CDMO with superior profitability and over 200 employees. He managed the acquisition of the company by Ajinomoto with an outstanding return on investment to shareholders.

Mr. Hancock began his biotechnology career at Hybritech Inc., (subsequently Eli Lilly and Company) one of the earliest companies developing monoclonal antibodies for diagnostic and therapeutic applications. He held positions of increasing responsibility in Quality Control, Process Development and cGMP Manufacturing. Following Hybritech, he worked at Genetics Institute, (currently a division of Pfizer) in the development and commercialization of several first to market products including recombinant Factor VIII, Factor IX and Bone Morphogenetic Protein. At The Immune Response Corporation, a developer of novel vaccine candidates to treat HIV infection, Multiple Sclerosis, Rheumatoid Arthritis and other autoimmune diseases, he established the company’s Manufacturing, Process Development and Quality organizations and was responsible for production and release of all clinical materials from early stage development and scale-up to commercial readiness.

Mr. Hancock currently serves as Executive Chairman of Argonaut Manufacturing Services, a CDMO producing a wide variety of medical devices, molecular diagnostics and parenteral drug products, and is a board member of Tempo Therapeutics.

He received a BA in Microbiology from Miami University, Oxford, Ohio.

Close this popup.
We use cookies to improve your experience on our site. To find out more, read our Privacy Policy.